Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | SNCA | P37840 | 1/20 | 0.55 |
| ▸ | PIP4K2C | Q8TBX8 | 3/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 9/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 7/20 | 0.52 |
| ▸ | BRD4 | O60885 | 4/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.49 |
| ▸ | FOXM1 | Q08050 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20641349 | 1.00 | MAPT (0.55) | MAPTSNCAPIP4K2CCRBNDDB1 | |
| SCHEMBL30544631 | 1.00 | MAPT (0.55) | MAPTSNCAPIP4K2CCRBNDDB1 | |
| SCHEMBL23418101 | 0.95 | STAT3 (0.55) | MAPTSNCAPIP4K2CCRBNDDB1 | |
| SCHEMBL23418132 | 0.93 | CRBN (0.56) | MAPTSNCACRBNSTAT3BRD9 | |
| SCHEMBL23418065 | 0.90 | DDB1 (0.48) | MAPTSNCAPIP4K2CCRBNDDB1 | |
| SCHEMBL27058197 | 0.88 | MAPT (0.44) | MAPTSNCAPIP4K2CCRBNDDB1 | |
| SCHEMBL20641332 | 0.85 | CRBN (0.52) | MAPTSNCAPIP4K2CCRBNDDB1 | |
| SCHEMBL23391718 | 0.85 | CRBN (0.52) | MAPTSNCAPIP4K2CCRBNDDB1 | |
| SCHEMBL30544628 | 0.85 | CRBN (0.52) | MAPTSNCAPIP4K2CCRBNDDB1 | |
| SCHEMBL20120282 | 0.85 | EGFR (0.53) | CRBNDDB1STAT3BRD9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4310496-A2 | COMPOUNDS FOR TAU PROTEIN DEGRADATION | Dana-Farber Cancer Institute, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-4310496-A2 | COMPOUNDS FOR TAU PROTEIN DEGRADATION | Dana-Farber Cancer Institute, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-3652329-B1 | COMPOUNDS FOR TAU PROTEIN DEGRADATION | DANA FARBER CANCER INST INC (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3652329-B1 | COMPOUNDS FOR TAU PROTEIN DEGRADATION | DANA FARBER CANCER INST INC (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20210154184-A1 | COMPOUNDS FOR TAU PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154184-A1 | COMPOUNDS FOR TAU PROTEIN DEGRADATION | UBQLN1, UBQLN2, CRBN | MAPT 4/4885SNCA 254/4885PIP4K2C 3940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.